BMC Cancer

Section Editors

Paolo Bruzzi, National Cancer Research Institute
Carlos Caldas, Cambridge Research Institute
Ian Cree, Warwick Medical School, Coventry
Shoukat Dedhar, British Columbia Cancer Agency
John A Hartley, University College London
Manami Inoue, University of Tokyo
Mark McKeage, University of Auckland
Christophe Nicot, Kansas University Medical Center
Stephen P Povoski, The Ohio State University
Dirk Vordermark, Martin Luther University Halle-Wittenberg

Executive Editor

Dafne Solera, BioMed Central

Editorial Board | Editorial Team | Instructions for authors | FAQ

Articles

There has been an error retrieving the data. Please try again.

Targeting microspheres to mesothelioma

Silica microparticles loaded with doxorubicin (DOX) and modified with a mesothelin specific antibody demonstrate higher effectiveness and lower toxicity than DOX systemic treatment in a mouse xenograft model of human peritoneal mesothelioma.

BMC Cancer 2013, 13:400
Multidisciplinary approach to cancer

Newly appointed Section Editor Stephen Povoski and Deputy Nathan Hall comment on plans to expand the scope of the BMC Cancer Clinical Oncology section, as surgical oncology and cancer imaging join forces with chemotherapy and radiation.

BMC Cancer 2013, 13:355
Biomarkers from the breast fluid secretome

Ferdinando Mannello and Daniela Ligi review breast cancer biomarkers that mirror the tumor microenvironment and discuss the potential of the nipple aspirate fluid secretome as a source of novel markers for early detection.

BMC Cancer 2013, 13:344
When the helpers hinder

When exposed to factors secreted from tumour cells, macrophages and monocytes release EGFR ligands and STAT3 activators to promote macrophage infiltration, tumour growth and dissemination in invasive breast cancer.

BMC Cancer 2013, 13:197
View more articles

RSS

Comments

No such thing as homeopathy?

Comment on: Rostock et al. BMC Cancer 2013, 11:19
Contrasting results from new study...?

Comment on: Rostock et al. BMC Cancer 2013, 11:19
Without homeopathic remedies, is care 'homeopathic'?

Comment on: Rostock et al. BMC Cancer 2013, 11:19

Hot topic

Nrf2 is required to maintain the self-renewal of glioma stem cells

Zhu J, Wang H, Sun Q, Ji X, Zhu L, Cong Z, Zhou Y, Liu H et al.

BMC Cancer 2013, 13:380

RSS

News from the web

30 September 2013: Use of <I>SHOX2</I> DNA measurement improves cancer staging tools

30 September 2013: Intercalated erlotinib/chemotherapy shows mixed results in NSCLC

27 September 2013: Time to first cigarette independently predicts lung cancer

Scope

BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions concerning molecular and cellular biology, genetics, epidemiology, and clinical trials.

It is journal policy to publish work deemed by peer reviewers to be a coherent and sound addition to scientific knowledge and to put less emphasis on interest levels, provided that the research constitutes a useful contribution to the field.

Join the Editorial Board!

Are you interested in becoming an Editorial Board member for BMC Cancer and helping to maintain the editorial standards and ethos of this growing journal? To volunteer as an Associate Editor, please simply contact us at bmccancer@biomedcentral.com, enclosing a summary of your research interests and relevant expertise. We look forward to hearing from you.

Latest review

Review

Christudas Morais, David W Johnson, David A Vesey, and Glenda C Gobe1

BMC Cancer 2013, 13:14 (10 January 2013)

Abstract | Full text | PDF | PubMed

Section Editor's profile

Mark McKeage is a medical oncologist and associate professor in the department of pharmacology and clinical pharmacology and co-director of the Auckland Cancer Society Research Centre at the university of Auckland, New Zealand. His current research focuses on how membrane transporters determine response and handling of platinum-based anticancer drugs. In addition, he leads a programme of phase I oncology trials at his centre.

"BMC Cancer is the leading Open Access international journal in the field of oncology. By publishing over 500 articles per year, BMC Cancer offers rapid dissemination of the most recent information of interest to the broad oncology science community."

Prof McKeage is the Section Editor of the Clinical oncology- medical oncology and pharmacology section of BMC Cancer.

RSS